Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURIFY Trial
NCT07672860Phase 2Recruiting
- Sponsor
- Jinling Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney injury (AKI) comparing UDCA with Placebo (2 arms). Primary endpoint: Incidence of Acute Kidney Injury at 48 hours. Started Jun 2026; status: recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT07672860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672860.